Impact of metabolic syndrome and its components on cardiovascular disease event rates in 4900 patients with type 2 diabetes assigned to placebo in the field randomised trial

• Main Authors: Scott, R, Donoghoe, M, Watts, G.F, O'Brien, R, Pardy, C, Taskinen, M.-R, Davis, T.M.E, Colman, P.G, Manning, P, Fulcher, G, Keech, A.C
• Other Authors: SURGERY
• Format: Article
• Published: 2020
• Subjects: creatinine; fenofibrate; hemoglobin A1c; high density lipoprotein cholesterol; placebo; triacylglycerol; antilipemic agent; glycosylated hemoglobin; hemoglobin A1c protein, human; adult; aged; article; cardiovascular disease; cardiovascular risk; controlled study; creatinine blood level; drug efficacy; dyslipidemia; female; human; hypertension; hypertriglyceridemia; kidney dysfunction; major clinical study; male; metabolic syndrome X; non insulin dependent diabetes mellitus; prevalence; randomized controlled trial; systolic blood pressure; treatment outcome; triacylglycerol blood level; waist circumference; waist hip ratio; world health organization; Australia; blood; clinical trial; cohort analysis; controlled clinical trial; Finland; metabolism; middle aged; New Zealand; pathophysiology; proportional hazards model; risk factor; Aged; Cardiovascular Diseases; Cholesterol, HDL; Cohort Studies; Diabetes Mellitus, Type 2; Female; Fenofibrate; Hemoglobin A, Glycosylated; Humans; Hypertension; Hypolipidemic Agents; Male; Metabolic Syndrome X; Middle Aged; Placebos; Proportional Hazards Models; Risk Factors; Triglycerides
• Online Access: https://scholarbank.nus.edu.sg/handle/10635/181621
• Institution: National University of Singapore

10.1186/1475-2840-10-102